-+ 0.00%
-+ 0.00%
-+ 0.00%
TOP-REAL investigates whether digital monitoring can support earlier detection of toxicities and preserve continuity of one of the most effective treatments for HER2-positive metastatic breast cancer
Share
Listen to the news

BARCELONA, Spain, Nov. 20, 2026 /PRNewswire/ -- Solti, an academic cancer clinical research group, has presented at the European ESMO AI & Digital Oncology 2026 congress the design of TOP-REAL, an international academic phase II study evaluating a proactive monitoring model for patients with advanced or metastatic HER2-positive breast cancer receiving first-line trastuzumab deruxtecan (T-DXd) plus pertuzumab.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending